CDXS logo

CODEXIS INC

CDXSNASDAQ
πŸ† #3825 by market capEarnings Oct 29US Equity
$1.20β–Ό $0.06 (βˆ’4.76%)
After hours Β· at close
πŸ””
Track CDXS
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 4.8%
7dβ–Ό 7.7%
14dβ–Ό 11.8%
30dβ–Ό 11.4%
ytdβ–Ό 26.2%
1yβ–Ό 50.4%
🏦Market Cap
$131M
Small Cap
πŸ“ˆRevenue Growth (YoY)
18.6%
Healthy
πŸ“ŠGross Margin
83.7%
High
πŸ’΅FCF Margin
-15.7%
Thin
βš–οΈP/S Ratio
1.8x
Cheap
Otter Score
β€”
Insufficient data

Trading Snapshot

Day Range
$1.20 – $1.29
52-Week Range
$0.96 – $2.98
Volume (shares)
76,470
Avg Volume (shares)
β€”
Shares Outstanding
109.5M
Next Earnings
2026-10-29

Fundamentals Snapshot

Annual Revenue
$70M
Last Q Revenue
$15M
P/E Ratio
-3.7
P/S Ratio
1.8x
EPS (TTM)
$-0.34
Dividend Yield
0.00%
Dilution (1yr)
+11.8%
CDXS logo

CODEXIS INC

CDXS
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$70Mβ–² +18.6% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
86.7%β–² +19.5% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$38Mβ–Ό βˆ’34.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$24Mβ–Ό βˆ’55.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
90.9Mβ–² +11.8% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$22Mβ–² +$18M YoY
StockOtter Β· stockotter.space

About CODEXIS INC

Codexis, Inc. is a biotechnology firm dedicated to the discovery, development, and commercialization of enzymes and other protein-based solutions. Its diverse portfolio encompasses advanced biocatalyst products and related services, specialized chemical intermediates vital for subsequent processing steps, and proprietary biocatalyst panels and kits that empower clients to conduct effective chemistry screening. The company also extends its expertise through biocatalyst screening and sophisticated protein engineering services. Central to its operations is the proprietary CodeEvolver protein engineering technology platform. This innovative platform is instrumental in crafting and delivering high-performance biocatalysts capable of driving chemical transformations, thereby significantly enhancing the efficiency and productivity of manufacturing processes. Beyond industrial applications, the CodeEvolver platform is also leveraged for identifying novel biotherapeutic drug candidates for targeted human diseases, as well as for developing enzymes essential for molecular biology research and in vitro diagnostic applications. Primarily serving pharmaceutical manufacturers, Codexis distributes its products through its dedicated direct sales and business development teams across the United States and Europe. Established in 2002, the company maintains its headquarters in Redwood City, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100
Analyst data unavailable.

Latest News & Updates

News unavailable.